Erturk Ayse, Akdogan Remzi Adnan, Parlak Emine, Cure Erkan, Cumhur Cure Medine, Ozturk Cinar
Department of Infectious Diseases, Recep Tayyip Erdoğan University, Rize, Turkey.
Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey.
Drug Des Devel Ther. 2014 May 29;8:621-5. doi: 10.2147/DDDT.S61045. eCollection 2014.
To analyze the effect of increasing Entecavir (ETV) dosage in patients with chronic hepatitis B (CHB) who partially responded to ETV after 1 year.
Twenty-three hepatitis B e antigen (HBeAg)-positive and 36 HBeAg-negative patients with CHB were treated with ETV 0.5 mg daily. After 1 year of the treatment, those with detectable hepatitis B virus (HBV-DNA) were randomized to either ETV 0.5 mg or 1 mg daily. The resistance to ETV was excluded. Both groups received ETV for 3 years. The groups were compared in aspects of undetectable DNA.
Group 1 was given 0.5 mg ETV and included 32 patients (20 HBeAg-negative and 12 HBeAg-positive). Group 2 was given 1 mg ETV and consisted of 27 patients (16 HBeAg-negative and eleven HBeAg-positive). Group 2 had more effective suppression of HBV-DNA while both groups had comparable rates of HBeAg loss (58% and 63% for group 1 and group 2, respectively) and alanine transaminase (ALT) normalization at the end of 4 years.
Increasing ETV dose from 0.5 mg to 1 mg after 1 year of ETV treatment may provide an effective suppression of viral replication.
分析对恩替卡韦（ETV）治疗1年后部分应答的慢性乙型肝炎（CHB）患者增加ETV剂量的效果。
23例乙肝e抗原（HBeAg）阳性和36例HBeAg阴性的CHB患者接受每日0.5mg ETV治疗。治疗1年后，HBV-DNA仍可检测到的患者被随机分为每日接受0.5mg或1mg ETV治疗两组。排除对ETV耐药的患者。两组均接受3年ETV治疗。比较两组HBV-DNA不可检测的情况。
第1组给予0.5mg ETV，包括32例患者（20例HBeAg阴性和12例HBeAg阳性）。第2组给予1mg ETV，由27例患者组成（16例HBeAg阴性和11例HBeAg阳性）。第2组对HBV-DNA的抑制作用更强，而两组在4年末的HBeAg血清学转换率（第1组和第2组分别为58%和63%）和谷丙转氨酶（ALT）复常率相当。
ETV治疗1年后将ETV剂量从0.5mg增加至1mg可能有效抑制病毒复制。
